BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (June 2020)
18 slides from BioSpecifics Technologies's investor presentation, Jun 12, 2020
Slide 1: Building a next-generation company on the foundation of our collagenase-based therapies
Building a next-generation company on the foundation of our collagenase-based therapies June 2020 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding
Slide 3: Company Overview
Company Overview (NASDAQ: BSTC) Strong cash position No debt Supported by royalty revenues from partner Endo for marketed XIAFLEX® indications Prudent cash management Continuing to maximize the XIAFLEX®/CCH portfolio Approved XIAFLEX® indications: Peyronie’s disease and Dupuytren’s contracture CCH f
Slide 4: Strong Balance Sheet to Support Future Growth Initiatives
Strong Balance Sheet to Support Future Growth Initiatives Lean corporate structure and strong balance sheet ~$113M in cash as of 3/31/20 $9.7M 1Q20 royalties received from Endo sales of XIAFLEX® 0 Debt Seeking to partner with companies that possess novel therapeutics that will deliver meaningful ben
Slide 5: Commercial and Development Pipeline
Commercial and Development Pipeline Collagenases are naturally occurring enzymes responsible for the breakdown of collagen Biopharmaceutical company that originated and continues to develop, in collaboration with Endo Pharmaceuticals, a first-in-class collagenase-based portfolio of commercial and cl
Slide 6: Multiple Conditions Associated with Collagen Accumulation
Multiple Conditions Associated with Collagen Accumulation Dupuytren’s contracture Peyronie’s disease Approved medical indications, marketed as XIAFLEX® CCH for Cellulite BLA under FDA review Adhesive capsulitis (frozen shoulder) Plantar fibromatosis XIAFLEX® medical indications for large unmet need
Slide 7: Diverse Pipeline
Diverse Pipeline Indication Preclinical Phase 1 Phase 2 Phase 3 Marketed XIAFLEX® COMMERCIAL INDICATIONS Dupuytren’s Contracture Peyronie’s Disease UNDER FDA REVIEW Cellulite XIAFLEX® DEVELOPMENT INDICATIONS Adhesive Capsulitis Plantar Fibromatosis Source: Endo International plc
Slide 8: XIAFLEX Commercial Indications
XIAFLEX® Commercial Indications
Slide 9: Peyronie's Disease
Peyronie’s Disease Can distort an erection and make sexual intercourse difficult or even impossible in advanced cases In some mild cases, the plaque can resolve spontaneously without medical intervention In severe cases, the penis can be bent at a 90-degree angle during erection Characterized by pre
Slide 10: Dupuytren's Contracture
Dupuytren’s Contracture Onset is characterized by the formation of nodules at the juncture between the fingers and palm that are composed primarily of collagen As the disease progresses, collagen nodules begin to form a cord causing the patient’s finger(s) to contract, making it impossible to open t
Slide 11: CCH for Cellulite
CCH for Cellulite Affects ~85-90% of post-pubertal females Currently no FDA-approved pharmaceutical products to address fibrous septae primarily composed of collagen Skin dimpling occurring mainly on the buttocks, thighs and lower abdomen and arms FDA Status BLA under FDA review with July 6, 2020 PD
Slide 12: XIAFLEX Development Pipeline
XIAFLEX® Development Pipeline
Slide 13: Adhesive Capsulitis
Adhesive Capsulitis Common available treatment options are often painful and can require anesthesia Long-term intensive physical therapy, corticosteroids, manipulation under anesthesia and /or arthroscopic release Condition can last ~1 year to up to 3.5 years Inflammation and thickening of shoulder
Slide 14: Plantar Fibromatosis
Plantar Fibromatosis Formation of nodules or cords along plantar fascia Patients often have Dupuytren’s disease, Peyronie’s disease and adhesive capsulitis Pain and disability caused by the thickening of the feet's deep connective tissue Market Opportunity ~3-3.5M patients with plantar fasciitis or
Slide 15: BSTC Corporate Overview
BSTC Corporate Overview S biospecifics
Slide 16: Financial Highlights from 1Q20
Financial Highlights from 1Q20 For the three months ended 3/31/2020 3/31/2019 Cash and equivalents, and investments $113,604,951 $88,132,205 Income Statement Revenues $9,668,667 $8,129,141 Other income 479,709 449,425 Costs and expenses (4,436,061) (3,056,696) Provision for income taxes (1,213,509)
Slide 17: Corporate Outlook and Upcoming Milestones
Corporate Outlook and Upcoming Milestones Continue to receive royalty revenues from partner Endo for marketed XIAFLEX® indications Royalty revenue grew 19% year-over-year for 1Q20 Endo expects full year 2020 revenues to be lower than 2019 due to COVID-19 IP through 2028 Opportunistic about Business
Slide 18: Building a next-generation company on the foundation of our collagenase-based therapies
Building a next-generation company on the foundation of our collagenase-based therapies June 2020
Biospecifics Technologies — Investor Presentation (June 2020) on 6ix